These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 9360780)

  • 1. Peptide analogs that inhibit IgE-Fc epsilon RI alpha interactions ameliorate the development of lethal graft-versus-host disease.
    Korngold R; Jameson BA; McDonnell JM; Leighton C; Sutton BJ; Gould HJ; Murphy GF
    Biol Blood Marrow Transplant; 1997 Oct; 3(4):187-93. PubMed ID: 9360780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation model.
    Choksi S; Kim JC; Whitaker-Menezes D; Murphy GF; Friedman TM; Korngold R
    Biol Blood Marrow Transplant; 2004 Oct; 10(10):669-80. PubMed ID: 15389433
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human IgE receptor alpha-chain IgG chimera blocks passive cutaneous anaphylaxis reaction in vivo.
    Haak-Frendscho M; Ridgway J; Shields R; Robbins K; Gorman C; Jardieu P
    J Immunol; 1993 Jul; 151(1):351-8. PubMed ID: 7686940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amino acid residues that influence Fc epsilon RI-mediated effector functions of human immunoglobulin E.
    Sayers I; Cain SA; Swan JR; Pickett MA; Watt PJ; Holgate ST; Padlan EA; Schuck P; Helm BA
    Biochemistry; 1998 Nov; 37(46):16152-64. PubMed ID: 9819207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thermodynamics of the interaction of human immunoglobulin E with its high-affinity receptor Fc epsilon RI.
    Keown MB; Henry AJ; Ghirlando R; Sutton BJ; Gould HJ
    Biochemistry; 1998 Jun; 37(25):8863-9. PubMed ID: 9636027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Affinity improvement of the high-affinity immunoglobulin E receptor by phage display.
    Iwasaki A; Doi T; Umetani M; Watanabe M; Suda M; Hattori Y; Nagoya T
    Biochem Biophys Res Commun; 2002 Apr; 293(1):542-8. PubMed ID: 12054635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fc epsilon receptor I on dendritic cells delivers IgE-bound multivalent antigens into a cathepsin S-dependent pathway of MHC class II presentation.
    Maurer D; Fiebiger E; Reininger B; Ebner C; Petzelbauer P; Shi GP; Chapman HA; Stingl G
    J Immunol; 1998 Sep; 161(6):2731-9. PubMed ID: 9743330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific donor Vbeta-associated CD4 T-cell responses correlate with severe acute graft-versus-host disease directed to multiple minor histocompatibility antigens.
    Jones SC; Friedman TM; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2004 Feb; 10(2):91-105. PubMed ID: 14750075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Ala12]MCD peptide: a lead peptide to inhibitors of immunoglobulin E binding to mast cell receptors.
    Buku A; Condie BA; Price JA; Mezei M
    J Pept Res; 2005 Sep; 66(3):132-7. PubMed ID: 16083440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of recombinant soluble Fc epsilon RI: function and tissue distribution studies.
    Gavin AL; Snider J; Hulett MD; Mckenzie IF; Hogarth PM
    Immunology; 1995 Nov; 86(3):392-8. PubMed ID: 8550076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation of canine-human Fc IgE chimeric antibodies for the determination of the canine IgE domain of interaction with Fc epsilon RI alpha.
    Hunter MJ; Vratimos AP; Housden JE; Helm BA
    Mol Immunol; 2008 Apr; 45(8):2262-8. PubMed ID: 18187193
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric immunoglobulin E reactive with tumor-associated antigen activates human Fc epsilon RI bearing cells.
    Luiten RM; Warnaar SO; Schuurman J; Pasmans SG; Latour S; Daëron M; Fleuren GJ; Litvinov SV
    Hum Antibodies; 1997; 8(4):169-80. PubMed ID: 9395919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fc(epsilon)RI and FcgammaRIII/CD16 differentially regulate atopic dermatitis in mice.
    Abboud G; Staumont-Sallé D; Kanda A; Roumier T; Deruytter N; Lavogiez C; Fleury S; Rémy P; Papin JP; Capron M; Dombrowicz D
    J Immunol; 2009 May; 182(10):6517-26. PubMed ID: 19414806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation.
    Asai O; Longo DL; Tian ZG; Hornung RL; Taub DD; Ruscetti FW; Murphy WJ
    J Clin Invest; 1998 May; 101(9):1835-42. PubMed ID: 9576746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease.
    Drobyski WR; Majewski D; Hanson G
    Biol Blood Marrow Transplant; 1999; 5(4):222-30. PubMed ID: 10465102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation.
    Edinger M; Hoffmann P; Ermann J; Drago K; Fathman CG; Strober S; Negrin RS
    Nat Med; 2003 Sep; 9(9):1144-50. PubMed ID: 12925844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative importance of CD4+ and CD8+ T cell repertoires in the development of acute graft-versus-host disease in a murine model of bone marrow transplantation.
    Miconnet I; de La Selle V; Bruley-Rosset M
    Bone Marrow Transplant; 1998 Mar; 21(6):583-90. PubMed ID: 9543062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proliferation-based T-cell selection for immunotherapy and graft-versus-host-disease prophylaxis in the context of bone marrow transplantation.
    Pachnio A; Dietrich S; Klapper W; Humpe A; Schwake M; Sedlacek R; Gramatzki M; Beck C
    Bone Marrow Transplant; 2006 Jul; 38(2):157-67. PubMed ID: 16820783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A metalloproteinase inhibitor prevents acute graft-versus-host disease while preserving the graft-versus-leukaemia effect of allogeneic bone marrow transplantation.
    Hattori K; Hirano T; Miyajima H; Yamakawa N; Ikeda S; Yoshino K; Tateno M; Oshimi K; Kayagaki N; Yagita H; Okumura K
    Br J Haematol; 1999 Apr; 105(1):303-12. PubMed ID: 10233398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antitumor IgE adjuvanticity: key role of Fc epsilon RI.
    Nigro EA; Brini AT; Soprana E; Ambrosi A; Dombrowicz D; Siccardi AG; Vangelista L
    J Immunol; 2009 Oct; 183(7):4530-6. PubMed ID: 19748979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.